Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
ESMO 2025
If approved, how will you choose between Disitamab Vedotin/Toripalimib (DV+T) and EV+Pembro (EV-303), in those patients with HER2+ mUC?
Related Questions
Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?
What are your top takeaways in GU Cancers from ESMO 2025?
Do the results of IMvigor011 influence you to utilize ctDNA to guide all adjuvant IO in MIBC?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Do you give fosaprepitant (or other NK1 antagonist) for emetogenic prophylaxis when giving ifosfamide-containing regimens?
What are your top takeaways in Gyn Cancers from ESMO 2025?
In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?
In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?
What are your top takeaways in Breast Cancer from ESMO 2025?
How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?
